[T lymphocyte activation induced in vivo by the first injection of OKT3 monoclonal antibodies].
One of the major side effects induced by the in vivo administration of the murine monoclonal antibody OKT3 is a spontaneously reversible clinical syndrome associating in variable proportions depending on the patient: fever, chills, headaches, diarrhea and seldomly meningismus. Sera from 3 renal allograft recipients treated with OKT3 were studied and showed that a massive although transient release of some cytokines namely, Tumor Necrosis Factor alpha, Interleukin 2 and Interferon gamma is observed following the first OKT3 injection.
Chatenoud
L
L
Hôpital Necker, Paris.
Ferran
C
C
Reuter
A
A
Legendre
C
C
Gevaert
Y
Y
Kreis
H
H
Franchimont
P
P
Bach
J F
JF
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D016030:Kidney Transplantation; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma
Activation lymphocytaire T induite in vivo par la première injection de l'anticorps monoclonal OKT3.